

Requirements for Pharmacist Review of Orders

CMS

A-0500

(Rev. 37, Issued: 10-17-08; Effective/Implementation Date: 10-17-08)

§482.25(b) Standard: Delivery of Services

In order to provide patient safety, drugs and biologicals must be controlled and distributed in accordance with applicable standards of practice, consistent with Federal and State law.

Interpretive Guidelines §482.25(b)

Drugs and biologicals must be controlled and distributed in accordance with applicable Federal and State laws and regulations, and in accordance with applicable standards of practice. Applicable standards of practice include compliance with all Federal and State laws, regulations, and guidelines, as well as, standards and recommendations promoted by nationally recognized professional organizations that apply to pharmaceutical care and the control and distribution of drugs and biologicals.

The procedures established to prevent unauthorized usage and distribution must provide for an accounting of the receipt and disposition of drugs subject to the Comprehensive Drug Abuse Prevention and Control Act of 1970.

The pharmacist, in consultation with appropriate hospital staff and committees, is to develop and implement guidelines, protocols, policies and procedures for the provision of pharmaceutical services that ensure patient safety through the appropriate control and distribution of medications, medication-related devices and biologicals.

For high risk medications and high-risk patients (pediatric, geriatric or patients with renal or hepatic impairment) there should be systems in place to minimize adverse drug events. Such systems could include but not limited to; checklists, dose limits, pre-printed orders, special packaging, special labeling, double-checks and written guidelines. **“High risk medications”** are those medications involved in a high percentage of medication errors and/or sentinel events and medications that carry a higher risk for abuse, errors, or other adverse outcomes. Lists of high-risk or high-alert drugs are available from such organizations as the Institute for Safe Medication Practices (ISMP) and the United States Pharmacopoeia (USP). Examples of high-risk drugs may include investigational drugs, controlled medications, medications not on the approved FDA list, medications with a narrow therapeutic range, psychotherapeutic medications and look-alike/sound-alike medications and those new to the market or new to the hospital.

All medication orders (except in emergency situations) should be reviewed for appropriateness by a pharmacist before the first dose is dispensed.

Review of medication orders should include:

Therapeutic appropriateness of a patient’s medication regimen;

Therapeutic duplication in the patient’s medication regimen;

Appropriateness of the drug, dose, frequency, route and method of administration;

Real or potential medication-medication, medication-food, medication-laboratory test and medication-disease interactions;

Real or potential allergies or sensitivities;

Variation from organizational criteria for use

Other contraindications;

The effects of medication(s) on patients are monitored to assure medication therapy is appropriate and minimizes the occurrence of adverse events. That monitoring process includes:

Clinical and laboratory data to evaluate the efficacy of medication therapy to anticipate or evaluate toxicity and adverse effects;

Physical signs and clinical symptoms relevant to the patient's medication therapy;

Assessing the patient's own perceptions about side effects, and, when appropriate, perceived efficacy.

Sterile products should be prepared and labeled in a suitable environment by appropriately trained and qualified personnel.

The pharmacy should participate in hospital decisions about emergency medication kits. The supply and provision of emergency medications stored in the kits must be consistent with standards of practice and appropriate for a specified age group or disease treatment as well as consistent with applicable Federal and State laws.

The pharmacy should be involved in the evaluation, use and monitoring of drug delivery systems, administration devices and automated drug-dispensing machines? The evaluation and monitoring should include the potential for medication errors.

There must be a process to report serious adverse drug reactions to the FDA in accordance with the MedWatch program.

There is a policy that addresses the use of medications brought into the hospital by patients or their families.

There is a process and policy to ensure that investigational medications are safety controlled and administered. Procedures for the use of investigational medications include the following: A written process for reviewing, approving, supervising and monitoring investigational medications specifying that when pharmacy services are provided, the pharmacy controls the storage, dispensing, labeling, and distribution of the investigational medication.

Medications dispensed by the hospital are retrieved when recalled or discontinued by the manufacturer or the Food and Drug Administration (FDA) for safety reasons.

The hospital pharmacy must ensure that medication orders are accurate and that medications are administered as ordered. The pharmacy should have a system to reconcile medications that are not administered, that remain in the patient's medication drawer, slot, etc., when the pharmacy inventories patient medications or restocks patient medications. The pharmacy should determine the reason the medications were not used. For example, did the patient refuse the medication, was there a clinical or treatment reason the medication was not used, or was the medication not used due to an error?

JOINT COMMISSION

2009 Standard MM.05.01.05, Element of Performance 1:

Before dispensing or removing medications from floor stock or from an automated storage and distribution device, a pharmacist reviews all medication orders or prescriptions unless a licensed independent practitioner controls the ordering, preparation, and administration of the medication or when a delay would harm the patient in an urgent situation (including sudden changes in a patient's clinical status), in accordance with law and regulation.